Clinical Trials

Phase 2/3 Active not recruiting

Lung Neoplasms

NCT06225596 2026-04-15

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06343402 2026-04-15

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

350 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06545331 2026-04-15

DELTA-101

BreastGastrointestinalThoracic

396 enrolled

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT06712316 2026-04-15

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

1,260 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06806852 2026-04-15

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

90 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07361510 2026-04-15

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

750 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Terminated

214 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04958239 2026-04-14

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Tumor-Agnostic

Neoplasms

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1/2 Active not recruiting

681 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06470763 2026-04-14

EXPAND-1

240 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06623422 2026-04-14

INTerpath-009

680 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT03486873 2026-04-13

MK-3475-587

Other hematologic neoplasm

3,500 enrolled

Hematologic Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04799054 2026-04-13

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

188 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04938817 2026-04-13

KEYNOTE-B98

Phase 1/2 Recruiting

110 enrolled

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06077760 2026-04-13

INTerpath-002

868 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06170788 2026-04-13

TroFuse-007

614 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

500 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06345729 2026-04-13

KANDLELIT-004

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06385080 2026-04-13

OrigAMI-4

Phase 1/2 Recruiting

287 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06469944 2026-04-13

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06743126 2026-04-13

SUPRAME

360 enrolled

Dermatologic

Melanoma, Cutaneous Malignant

NCT06793215 2026-04-13

Krascendo 2

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06841354 2026-04-13

TroFuse-011